Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
CRAIGAVON, Northern Ireland, March 08, 2016 -- Almac Group – a contract research organization headquartered in Northern Ireland, with operations across the U.S. – announced today that its Diagnostics Business Unit will open a companion diagnostic development facility located in Research Triangle Park, N.C. The facility will provide a U.S. base to support Almac’s increased demand for its Companion Diagnostics (CDx) development partnerships as well as a Clinical Laboratory Improvement Amendments (CLIA)-accredited laboratory to support the downstream delivery of assays for patient testing.
Along with headquarters in Europe and partnerships in Asia, this facility will provide Almac Diagnostics with a strong global presence to continue to meet increasing customer demand and to support its growing client base. With more than 4,000 employees across the globe and more than 1,200 in the U.S., Almac continues to grow in employee number and footprint with this North Carolina location.
The 150,000-square-foot, custom-designed facility contains molecular biology laboratories, as well as office space. The state-of-the-art laboratory is equipped with microarray and quantitative Polymerase Chain Reaction (qPCR) platforms appropriate for companion diagnostic development; it will operate both research-use-only and clinical diagnostic tests. Plans are also in place to add additional technology platforms including Next-Generation Sequencing (NGS) in the coming year.
“The opening of our new CDx facility in the U.S. is Almac Diagnostics’ latest initiative to better serve our global Biopharma partners. As we experience increased client demand for our companion diagnostic development services, this latest expansion will significantly enhance Almac’s offering, increasing capacity and further demonstrating our commitment to personalized healthcare,” said Professor Paul Harkin, President and Managing Director of Almac Diagnostics.
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organization that has organically grown over 40 years and now employs in excess of 4,000 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).
Almac Diagnostics is one of five business units operating under the ownership of the Almac Group. The global company partners with the biopharmaceutical industry supporting the discovery, development and delivery of companion diagnostics. In addition, Almac Diagnostics has a pipeline of proprietary oncology based tests in development in therapeutic areas including breast, colon, ovarian, prostate and lung cancer.
For more information, visit www.almacgroup.com or e-mail [email protected].
CONTACT: Nicole Lasorda Buchanan Public Relations 610.228.0454 [email protected]
